Breast Cancer
Hormone receptor-positive breast cancer
Breast cancer is the most commonly diagnosed cancer in women worldwide. Hormone receptor-positive (HR+) breast cancer, which accounts for approximately 70–80% of all cases, relies on oestrogen and progesterone to grow. Innovarus is developing a long-acting injectable formulation to deliver sustained hormonal suppression — reducing the burden of frequent treatment visits for patients.
Prevalence
2.3M new cases/year globally
Our Focus
Long-acting hormonal suppression
Learn more →Symptoms · Treatment · Patient guide
Prostate Cancer
Androgen deprivation therapy
Prostate cancer is the most frequently diagnosed cancer in men across more than half the world's countries. Androgen deprivation therapy (ADT) via LHRH agonists is the cornerstone of treatment for advanced disease. Innovarus is developing a long-acting ISFI-based formulation to provide sustained testosterone suppression over 3–6 months from a single injection.
Prevalence
1.4M new cases/year globally
Our Focus
Sustained testosterone suppression
Learn more →Symptoms · Treatment · Patient guide
Acromegaly
Growth hormone excess — rare pituitary disorder
Acromegaly is a rare hormonal disorder caused by excess growth hormone (GH), most commonly due to a benign pituitary adenoma. It leads to abnormal bone growth, enlarged organs, and serious cardiovascular and metabolic complications. Somatostatin receptor ligands (SRLs) are the primary medical therapy. Innovarus is developing a long-acting ISFI formulation to deliver sustained GH suppression, reducing the need for monthly injections.
Prevalence
~60 cases per million people
Our Focus
Sustained somatostatin receptor ligand delivery
Learn more →Symptoms · Treatment · Patient guide
GEP-NET
Gastroenteropancreatic neuroendocrine tumours
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rare, slow-growing cancers arising from neuroendocrine cells of the gastrointestinal tract and pancreas. They can cause debilitating hormonal syndromes, including carcinoid syndrome. Long-acting somatostatin analogues are the standard of care for symptom control and anti-tumour therapy. Innovarus is developing a next-generation ISFI platform to improve dosing flexibility and patient convenience.
Prevalence
~5 cases per 100,000 people
Our Focus
Long-acting somatostatin analogue delivery
Learn more →Symptoms · Treatment · Patient guide
Polycystic Liver Disease
Progressive cystic liver disorder
Polycystic liver disease (PLD) is a rare genetic condition characterised by the progressive development of multiple fluid-filled cysts throughout the liver. In severe cases, massive hepatomegaly causes debilitating symptoms including abdominal pain, breathlessness, and malnutrition. Somatostatin analogues have demonstrated efficacy in reducing liver volume. Innovarus is developing a long-acting ISFI formulation to provide sustained therapeutic benefit with fewer injections.
Prevalence
~1 in 158,000 people
Our Focus
Long-acting somatostatin analogue for liver volume reduction
Learn more →Symptoms · Treatment · Patient guide
